Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Usana Health Sciences (USNA) Current Deferred Revenue (2016 - 2022)

Usana Health Sciences (USNA) has disclosed Current Deferred Revenue for 10 consecutive years, with $19.6 million as the latest value for Q1 2022.

  • On a quarterly basis, Current Deferred Revenue rose 23.09% to $19.6 million in Q1 2022 year-over-year; TTM through Jan 2022 was $19.6 million, a 23.09% increase, with the full-year FY2022 number at $19.6 million, up 23.09% from a year prior.
  • Current Deferred Revenue was $19.6 million for Q1 2022 at Usana Health Sciences, up from $16.0 million in the prior quarter.
  • In the past five years, Current Deferred Revenue ranged from a high of $19.6 million in Q1 2022 to a low of $2.6 million in Q4 2018.
  • A 4-year average of $13.0 million and a median of $14.9 million in 2019 define the central range for Current Deferred Revenue.
  • Peak YoY movement for Current Deferred Revenue: fell 13.61% in 2018, then skyrocketed 423.51% in 2019.
  • Usana Health Sciences' Current Deferred Revenue stood at $2.6 million in 2018, then surged by 423.51% to $13.9 million in 2019, then grew by 15.16% to $16.0 million in 2021, then grew by 23.09% to $19.6 million in 2022.
  • Per Business Quant, the three most recent readings for USNA's Current Deferred Revenue are $19.6 million (Q1 2022), $16.0 million (Q1 2021), and $13.9 million (Q4 2019).